The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Editas Medicine reset its pipeline, abandoning ex vivo assets due to market saturation, and now focuses solely on in vivo gene editing, specifically EDIT-401. I rate EDIT a hold, as EDIT-401 is ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Shares of Editas Medicine fell after the company said it has commenced an underwritten public offering of its common stock and warrants. The stock slipped 16%, to $2.31, in premarket trading Tuesday.

CAMBRIDGE, Mass., May 26, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company developing transformative medicines for serious diseases, today announced ...

A monthly overview of things you need to know as an architect or aspiring architect. Unlock the full InfoQ experience by logging in! Stay updated with your favorite authors and topics, engage with ...

CAMBRIDGE, Mass.(AP) — CAMBRIDGE, Mass. (AP) — Editas Medicine Inc. (EDIT) on Tuesday reported a loss of $25 million in its first quarter. The Cambridge, Massachusetts-based company said it had a loss ...

When looking only at the past 12 months, Editas Medicine (NASDAQ: EDIT), a small-cap biotech company, seems to be doing well. The drugmaker's shares have soared by 80% over this period. However, ...